Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 201

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

Herrlinger, Ulrich, Schäfer, Niklas, Steinbach, Joachim P., Weyerbrock, Astrid, Hau, Peter, Goldbrunner, Roland, Friedrich, Franziska, Rohde, Veit, Ringel, Florian, Schlegel, Uwe, Sabel, Michael, Ronellenfitsch, Michael W., Uhl, Martin, Maciaczyk, Jaroslaw, Grau, Stefan, Schnell, Oliver, Hänel, Mathias, Krex, Dietmar, Vajkoczy, Peter, Gerlach, Rüdiger, Kortmann, Rolf-Dieter, Mehdorn, Maximilian, Tüttenberg, Jochen, Mayer-Steinacker, Regine, Fietkau, Rainer, Brehmer, Stefanie, Mack, Frederic, Stuplich, Moritz, Kebir, Sied, Kohnen, Ralf, Dunkl, Elmar, Leutgeb, Barbara, Proescholdt, Martin, Pietsch, Torsten, Urbach, Horst, Belka, Claus, Stummer, Walter, Glas, Martin·2016·Journal of Clinical Oncology

Abstract

Purpose: In patients with newly diagnosed glioblastoma that harbors a nonmethylated O 6-methylguanine–DNA methyltransferase promotor, standard temozolomide (TMZ) has, at best, limited efficacy. The GLARIUS trial thus explored bevacizumab plus irinotecan (BEV+IRI) as an alternative to TMZ. Patients and Methods: In this phase II, unblinded trial 182 patients in 22 centers were randomly assigned 2:1 to BEV (10 mg/kg every 2 weeks) during radiotherapy (RT) followed by maintenance BEV (10 mg/kg every 2 weeks) plus IRI(125 mg/m 2 every 2 weeks) or to daily TMZ (75 mg/m 2) during RT followed by six courses of TMZ (150-200 mg/m 2/d for 5 days every 4 weeks). The primary end point was the progression-free survival rate after 6 months (PFS-6). Results: In the modified intention-to-treat (ITT) population, PFS-6 was increased from 42.6% with TMZ (95% CI, 29.4% to 55.8%) to 79.3% with BEV+IRI (95% CI, 71.9% to 86.7%; P <.001). PFS was prolonged from a median of 5.99 months (95% CI, 2.7 to 7.3 months) to 9.7 months (95% CI, 8.7 to 10.8 months; P < .001). At progression, crossover BEV therapy was given to 81.8% of all patients who received any sort of second-line therapy in the TMZ arm. Overall survival (OS) was not different in the two arms: the median OS was 16.6 months (95% CI, 15.4 to 18.4 months) with BEV+IRI and was 17.5 months (95% CI, 15.1 to 20.5 months) with TMZ. The time course of quality of life (QOL) in six selected domains of the European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire (QLQ) –C30 and QLQ-BN20 (which included cognitive functioning), of the Karnofsky performance score, and of the Mini Mental State Examination score was not different between the treatment arms. Conclusion: BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ. However, BEV+IRI did not improve OS, potentially because of the high crossover rate. BEV+IRI did not alter QOL compared with TMZ.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.63.4691

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 201

Metadata

Authors
Herrlinger, U., Schäfer, N., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Friedrich, F., Rohde, V., Ringel, F., Schlegel, U., Sabel, M., Ronellenfitsch, M. W., Uhl, M., Maciaczyk, J., Grau, S., Schnell, O., Hänel, M., Krex, D., Vajkoczy, P., Gerlach, R., Kortmann, R.-D., Mehdorn, M., Tüttenberg, J., Mayer-Steinacker, R., Fietkau, R., Brehmer, S., Mack, F., Stuplich, M., Kebir, S., Kohnen, R., Dunkl, E., Leutgeb, B., Proescholdt, M., Pietsch, T., Urbach, H., Belka, C., Stummer, W., & Glas, M.
Venue
Journal of Clinical Oncology
Published
2016-05-10
Volume
34
Issue
14
Pages
1611-1619
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2300412351
Cited by
201
References
6
FWCI
16.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. https://app.cochat.ai/papers/10.1200/jco.2015.63.4691
The paper
Herrlinger, U., Schäfer, N., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Friedrich, F., Rohde, V., Ringel, F., Schlegel, U., Sabel, M., Ronellenfitsch, M. W., Uhl, M., Maciaczyk, J., Grau, S., Schnell, O., Hänel, M., Krex, D., Vajkoczy, P., . . . Glas, M. (2016). Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.63.4691

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.